Microbiome Therapeutics Market Forecasts to 2032 – Global Analysis By Therapeutic Type (Live, Biotherapeutic Products (LBPs), Microbiome-Derived Small Molecules, Prebiotics & Probiotics (Therapeutic-Grade), Postbiotics, Phage Therapy and Other Therapeutic
Description
According to Stratistics MRC, the Global Microbiome Therapeutics Market is accounted for $245.6 billion in 2025 and is expected to reach $2259.3 billion by 2032 growing at a CAGR of 37.3% during the forecast period. Microbiome therapeutics refers to a class of medical treatments designed to modulate or restore the human microbiome—the complex community of microorganisms residing in and on the body—to improve health or treat disease. These therapies target the gut, skin, or other microbial environments to correct imbalances linked to conditions such as inflammatory bowel disease, obesity, metabolic disorders, and infections. Approaches include probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and next-generation live biotherapeutics. By influencing microbial composition and function, microbiome therapeutics aim to enhance immunity, metabolism, and overall well-being in a precise, personalized manner.
Market Dynamics:
Driver:
Rising prevalence of gastrointestinal disorders
Healthcare providers are exploring therapeutic-grade formulations to address conditions such as IBS, Crohn’s disease, and ulcerative colitis. Research institutions are validating strain-specific efficacy for inflammation control and gut barrier restoration. Partnerships between biotech firms and clinical networks are accelerating product development. Regulatory bodies are supporting fast-track approvals for high-need indications. The market is shifting toward condition-specific microbiome therapies.
Restraint:
High research and development costs
Clinical trials for microbiome therapeutics require long timelines, complex protocols, and specialized infrastructure. Manufacturing live biotherapeutics demands stringent quality control and cold-chain logistics. Small and mid-sized players face funding gaps and regulatory hurdles. Intellectual property protection remains challenging due to strain variability and formulation complexity. These constraints are slowing market entry and product diversification.
Opportunity:
Consumer shift towards preventive healthcare
Individuals are seeking non-invasive solutions to improve immunity, digestion, and metabolic health. Therapeutic-grade probiotics and prebiotics are gaining traction in clinical and wellness settings. Integration with personalized nutrition platforms is enhancing relevance and engagement. Retail and digital health channels are broadening access to microbiome-based products. This momentum is redefining the boundary between therapeutic and preventive care.
Threat:
Limited clinical evidence for broad applications
Many microbiome therapies lack large-scale, peer-reviewed validation across diverse populations. Variability in strain performance and host response complicates standardization. Absence of harmonized guidelines is slowing integration into mainstream treatment protocols. Payers and providers remain cautious about reimbursement and long-term efficacy. These gaps are prompting calls for stronger clinical frameworks and post-market surveillance.
Covid-19 Impact:
The pandemic highlighted the role of gut health in immunity and recovery, boosting interest in microbiome therapeutics. Research into post-Covid inflammation and long-haul symptoms accelerated development of targeted formulations. Hospitals and wellness providers expanded use of probiotics and prebiotics to support immune resilience. Supply chain disruptions temporarily affected raw material availability and cold-chain logistics. Recovery efforts are driving investment in scalable, shelf-stable microbiome products. The crisis elevated microbiome health from niche interest to strategic priority.
The prebiotics & probiotics (Therapeutic-Grade) segment is expected to be the largest during the forecast period
The prebiotics & probiotics (Therapeutic-Grade) segment is expected to account for the largest market share during the forecast period due to their clinical relevance, safety profile, and scalability. These formulations are being used to manage gastrointestinal, metabolic, and immune-related conditions. Hospitals and specialty clinics are integrating them into treatment protocols for chronic and acute disorders. Vendors are optimizing strain combinations and delivery formats for targeted efficacy. Regulatory approvals and consumer trust are reinforcing segment dominance. This category anchors the commercial foundation of microbiome therapeutics.
The live biotherapeutic products (LBPs) segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the live biotherapeutic products (LBPs) segment is predicted to witness the highest growth rate as precision microbiome engineering gains momentum. These therapies involve genetically characterized strains designed for specific clinical outcomes. Research into fecal microbiota transplantation and synthetic consortia is expanding therapeutic scope. Biotech firms are developing delivery systems that ensure viability and targeted colonization. Investment in GMP manufacturing and regulatory alignment is accelerating clinical translation.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced research ecosystem, regulatory support, and consumer awareness. The United States and Canada are scaling microbiome trials across academic, clinical, and commercial settings. Investment in biotech startups and translational research is driving innovation. Presence of leading probiotic manufacturers and digital health platforms is reinforcing market strength. Reimbursement pathways and clinical guidelines are supporting therapeutic adoption. The region remains the benchmark for microbiome commercialization.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare access, wellness demand, and research investment expand. Countries like China, Japan, South Korea, and India are scaling microbiome initiatives across clinical and consumer domains. Government-backed health programs and startup ecosystems are accelerating product development. Local manufacturers are launching culturally tailored formulations and delivery formats. Rising interest in gut health and preventive care is boosting adoption across demographics.
Key players in the market
Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Finch Therapeutics Group, Vedanta Biosciences, Rebiotix Inc., 4D Pharma plc, Evelo Biosciences, Second Genome, Symbiome Inc., BiomX Inc., Axial Therapeutics, Kaleido Biosciences, DayTwo, Viome Life Sciences, LNC Therapeutics and Pendulum Therapeutics.
Key Developments:
In June 2024, Seres Therapeutics entered into a Memorandum of Understanding with Nestlé Health Science for the sale of its microbiome therapeutic, VOWST. The transaction was finalized, with Nestlé acquiring full ownership of VOWST, including all related intellectual property rights.
In March 2022, 4D Pharma entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. This partnership aimed to evaluate the combination of 4D Pharma's lead immuno-oncology candidate, MRx0518, with Merck's anti-PD-L1 antibody, avelumab, in patients with advanced solid tumors.
Therapeutic Types Covered:
• Live Biotherapeutic Products (LBPs)
• Microbiome-Derived Small Molecules
• Prebiotics & Probiotics (Therapeutic-Grade)
• Postbiotics
• Phage Therapy
• Fecal Microbiota Transplantation (FMT)
• Other Therapeutic Types
Indications Covered:
• Gastrointestinal Disorders
• Metabolic Disorders
• Oncology & Immunotherapy Modulation
• Neurological & Psychiatric Conditions
• Skin Disorders
• Infectious Diseases
• Women’s Health
• Other Indications
Delivery Modes Covered:
• Oral Capsules
• Liquids & Suspensions
• Rectal/Enema Formulations
• Injectable Formats
• Other Delivery Modes
End Users Covered:
• Hospitals & Specialty Clinics
• Research Institutes
• Biotech & Pharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Academic Medical Centers
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Market Dynamics:
Driver:
Rising prevalence of gastrointestinal disorders
Healthcare providers are exploring therapeutic-grade formulations to address conditions such as IBS, Crohn’s disease, and ulcerative colitis. Research institutions are validating strain-specific efficacy for inflammation control and gut barrier restoration. Partnerships between biotech firms and clinical networks are accelerating product development. Regulatory bodies are supporting fast-track approvals for high-need indications. The market is shifting toward condition-specific microbiome therapies.
Restraint:
High research and development costs
Clinical trials for microbiome therapeutics require long timelines, complex protocols, and specialized infrastructure. Manufacturing live biotherapeutics demands stringent quality control and cold-chain logistics. Small and mid-sized players face funding gaps and regulatory hurdles. Intellectual property protection remains challenging due to strain variability and formulation complexity. These constraints are slowing market entry and product diversification.
Opportunity:
Consumer shift towards preventive healthcare
Individuals are seeking non-invasive solutions to improve immunity, digestion, and metabolic health. Therapeutic-grade probiotics and prebiotics are gaining traction in clinical and wellness settings. Integration with personalized nutrition platforms is enhancing relevance and engagement. Retail and digital health channels are broadening access to microbiome-based products. This momentum is redefining the boundary between therapeutic and preventive care.
Threat:
Limited clinical evidence for broad applications
Many microbiome therapies lack large-scale, peer-reviewed validation across diverse populations. Variability in strain performance and host response complicates standardization. Absence of harmonized guidelines is slowing integration into mainstream treatment protocols. Payers and providers remain cautious about reimbursement and long-term efficacy. These gaps are prompting calls for stronger clinical frameworks and post-market surveillance.
Covid-19 Impact:
The pandemic highlighted the role of gut health in immunity and recovery, boosting interest in microbiome therapeutics. Research into post-Covid inflammation and long-haul symptoms accelerated development of targeted formulations. Hospitals and wellness providers expanded use of probiotics and prebiotics to support immune resilience. Supply chain disruptions temporarily affected raw material availability and cold-chain logistics. Recovery efforts are driving investment in scalable, shelf-stable microbiome products. The crisis elevated microbiome health from niche interest to strategic priority.
The prebiotics & probiotics (Therapeutic-Grade) segment is expected to be the largest during the forecast period
The prebiotics & probiotics (Therapeutic-Grade) segment is expected to account for the largest market share during the forecast period due to their clinical relevance, safety profile, and scalability. These formulations are being used to manage gastrointestinal, metabolic, and immune-related conditions. Hospitals and specialty clinics are integrating them into treatment protocols for chronic and acute disorders. Vendors are optimizing strain combinations and delivery formats for targeted efficacy. Regulatory approvals and consumer trust are reinforcing segment dominance. This category anchors the commercial foundation of microbiome therapeutics.
The live biotherapeutic products (LBPs) segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the live biotherapeutic products (LBPs) segment is predicted to witness the highest growth rate as precision microbiome engineering gains momentum. These therapies involve genetically characterized strains designed for specific clinical outcomes. Research into fecal microbiota transplantation and synthetic consortia is expanding therapeutic scope. Biotech firms are developing delivery systems that ensure viability and targeted colonization. Investment in GMP manufacturing and regulatory alignment is accelerating clinical translation.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share due to its advanced research ecosystem, regulatory support, and consumer awareness. The United States and Canada are scaling microbiome trials across academic, clinical, and commercial settings. Investment in biotech startups and translational research is driving innovation. Presence of leading probiotic manufacturers and digital health platforms is reinforcing market strength. Reimbursement pathways and clinical guidelines are supporting therapeutic adoption. The region remains the benchmark for microbiome commercialization.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare access, wellness demand, and research investment expand. Countries like China, Japan, South Korea, and India are scaling microbiome initiatives across clinical and consumer domains. Government-backed health programs and startup ecosystems are accelerating product development. Local manufacturers are launching culturally tailored formulations and delivery formats. Rising interest in gut health and preventive care is boosting adoption across demographics.
Key players in the market
Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Finch Therapeutics Group, Vedanta Biosciences, Rebiotix Inc., 4D Pharma plc, Evelo Biosciences, Second Genome, Symbiome Inc., BiomX Inc., Axial Therapeutics, Kaleido Biosciences, DayTwo, Viome Life Sciences, LNC Therapeutics and Pendulum Therapeutics.
Key Developments:
In June 2024, Seres Therapeutics entered into a Memorandum of Understanding with Nestlé Health Science for the sale of its microbiome therapeutic, VOWST. The transaction was finalized, with Nestlé acquiring full ownership of VOWST, including all related intellectual property rights.
In March 2022, 4D Pharma entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. This partnership aimed to evaluate the combination of 4D Pharma's lead immuno-oncology candidate, MRx0518, with Merck's anti-PD-L1 antibody, avelumab, in patients with advanced solid tumors.
Therapeutic Types Covered:
• Live Biotherapeutic Products (LBPs)
• Microbiome-Derived Small Molecules
• Prebiotics & Probiotics (Therapeutic-Grade)
• Postbiotics
• Phage Therapy
• Fecal Microbiota Transplantation (FMT)
• Other Therapeutic Types
Indications Covered:
• Gastrointestinal Disorders
• Metabolic Disorders
• Oncology & Immunotherapy Modulation
• Neurological & Psychiatric Conditions
• Skin Disorders
• Infectious Diseases
• Women’s Health
• Other Indications
Delivery Modes Covered:
• Oral Capsules
• Liquids & Suspensions
• Rectal/Enema Formulations
• Injectable Formats
• Other Delivery Modes
End Users Covered:
• Hospitals & Specialty Clinics
• Research Institutes
• Biotech & Pharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Academic Medical Centers
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Microbiome Therapeutics Market, By Therapeutic Type
- 5.1 Introduction
- 5.2 Live Biotherapeutic Products (LBPs)
- 5.3 Microbiome-Derived Small Molecules
- 5.4 Prebiotics & Probiotics (Therapeutic-Grade)
- 5.5 Postbiotics
- 5.6 Phage Therapy
- 5.7 Fecal Microbiota Transplantation (FMT)
- 5.8 Other Therapeutic Types
- 6 Global Microbiome Therapeutics Market, By Indication
- 6.1 Introduction
- 6.2 Gastrointestinal Disorders
- 6.3 Metabolic Disorders
- 6.4 Oncology & Immunotherapy Modulation
- 6.5 Neurological & Psychiatric Conditions
- 6.6 Skin Disorders
- 6.7 Infectious Diseases
- 6.8 Women’s Health
- 6.9 Other Indications
- 7 Global Microbiome Therapeutics Market, By Delivery Mode
- 7.1 Introduction
- 7.2 Oral Capsules
- 7.3 Liquids & Suspensions
- 7.4 Rectal/Enema Formulations
- 7.5 Injectable Formats
- 7.6 Other Delivery Modes
- 8 Global Microbiome Therapeutics Market, By End User
- 8.1 Introduction
- 8.2 Hospitals & Specialty Clinics
- 8.3 Research Institutes
- 8.4 Biotech & Pharmaceutical Companies
- 8.5 Contract Development & Manufacturing Organizations (CDMOs)
- 8.6 Academic Medical Centers
- 8.7 Other End Users
- 9 Global Microbiome Therapeutics Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
- 10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
- 11 Company Profiling
- 11.1 Seres Therapeutics
- 11.2 Finch Therapeutics Group
- 11.3 Vedanta Biosciences
- 11.4 Rebiotix Inc.
- 11.5 4D Pharma plc
- 11.6 Evelo Biosciences
- 11.7 Second Genome
- 11.8 Symbiome Inc.
- 11.9 BiomX Inc.
- 11.10 Axial Therapeutics
- 11.11 Kaleido Biosciences
- 11.12 DayTwo
- 11.13 Viome Life Sciences
- 11.14 LNC Therapeutics
- 11.15 Pendulum Therapeutics
- List of Tables
- Table 1 Global Microbiome Therapeutics Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Microbiome Therapeutics Market Outlook, By Therapeutic Type (2024-2032) ($MN)
- Table 3 Global Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (LBPs) (2024-2032) ($MN)
- Table 4 Global Microbiome Therapeutics Market Outlook, By Microbiome-Derived Small Molecules (2024-2032) ($MN)
- Table 5 Global Microbiome Therapeutics Market Outlook, By Prebiotics & Probiotics (Therapeutic-Grade) (2024-2032) ($MN)
- Table 6 Global Microbiome Therapeutics Market Outlook, By Postbiotics (2024-2032) ($MN)
- Table 7 Global Microbiome Therapeutics Market Outlook, By Phage Therapy (2024-2032) ($MN)
- Table 8 Global Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplantation (FMT) (2024-2032) ($MN)
- Table 9 Global Microbiome Therapeutics Market Outlook, By Other Therapeutic Types (2024-2032) ($MN)
- Table 10 Global Microbiome Therapeutics Market Outlook, By Indication (2024-2032) ($MN)
- Table 11 Global Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
- Table 12 Global Microbiome Therapeutics Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
- Table 13 Global Microbiome Therapeutics Market Outlook, By Oncology & Immunotherapy Modulation (2024-2032) ($MN)
- Table 14 Global Microbiome Therapeutics Market Outlook, By Neurological & Psychiatric Conditions (2024-2032) ($MN)
- Table 15 Global Microbiome Therapeutics Market Outlook, By Skin Disorders (2024-2032) ($MN)
- Table 16 Global Microbiome Therapeutics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
- Table 17 Global Microbiome Therapeutics Market Outlook, By Women’s Health (2024-2032) ($MN)
- Table 18 Global Microbiome Therapeutics Market Outlook, By Other Indications (2024-2032) ($MN)
- Table 19 Global Microbiome Therapeutics Market Outlook, By Delivery Mode (2024-2032) ($MN)
- Table 20 Global Microbiome Therapeutics Market Outlook, By Oral Capsules (2024-2032) ($MN)
- Table 21 Global Microbiome Therapeutics Market Outlook, By Liquids & Suspensions (2024-2032) ($MN)
- Table 22 Global Microbiome Therapeutics Market Outlook, By Rectal/Enema Formulations (2024-2032) ($MN)
- Table 23 Global Microbiome Therapeutics Market Outlook, By Injectable Formats (2024-2032) ($MN)
- Table 24 Global Microbiome Therapeutics Market Outlook, By Other Delivery Modes (2024-2032) ($MN)
- Table 25 Global Microbiome Therapeutics Market Outlook, By End User (2024-2032) ($MN)
- Table 26 Global Microbiome Therapeutics Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
- Table 27 Global Microbiome Therapeutics Market Outlook, By Research Institutes (2024-2032) ($MN)
- Table 28 Global Microbiome Therapeutics Market Outlook, By Biotech & Pharmaceutical Companies (2024-2032) ($MN)
- Table 29 Global Microbiome Therapeutics Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2024-2032) ($MN)
- Table 30 Global Microbiome Therapeutics Market Outlook, By Academic Medical Centers (2024-2032) ($MN)
- Table 31 Global Microbiome Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.